Biotech

All Articles

AstraZeneca posts records on internal competitors to AbbVie, Pfizer ADCs

.AstraZeneca has discussed a very early take a look at the functionality of its own in-house antibod...

iTeos- GSK's TIGIT star reveals significant renovation

.After introducing a stage 3 launch based upon beneficial midstage results, iTeos and also GSK are a...

More collective FDA can easily increase rare disease R&ampD: file

.The FDA needs to be actually even more open and also joint to discharge a rise in commendations of ...

Zenas, MBX, Bicara head to Nasdaq in warm time for biotech IPOs

.It is actually an abnormally occupied Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara...

Atea's COVID antiviral neglects to halt hospital stays in phase 3

.Atea Pharmaceuticals' antiviral has actually failed yet another COVID-19 trial, however the biotech...

Neurocrine's offer to spare mental illness prospect neglects

.Neurocrine Biosciences' schizophrenia system pivot has actually neglected. The biotech was not able...

Sanofi pays out $110M upfront for late-stage radioligand therapy

.Sanofi has made a late access to the radioligand party, paying 100 million europeans ($ 110 million...

F 2G raises $100M for 2nd effort to acquire brand new antifungal to market

.After F2G's first try to obtain a new lesson of antifungal to market was derailed by the FDA, the U...

Moderna targets $1.1 B in R&ampD costs cuts, falls 5 plans amid earnings tensions

.Moderna has actually vowed to reduce R&ampD spending through $1.1 billion by 2027. The choice to re...

Sanofi's $80M bet on Pivot dystrophy drug ends in period 3 go bust

.Only four months after Sanofi wager $80 thousand in ahead of time cash money on Key Therapies' losm...